The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

Ligand Rings the Opening Bell May 19, 2025 — 9:15 AM - 9:45 AM ET Nasdaq MarketSite, 4 Times Square, New York About This Event ...

Last April, Ligand established the Pelthos unit, with Zelsuvmi serving as its lead product. Experienced biotech leader Scott Plesha was tapped as CEO, a role he will continue to hold at the newly ...

In the pre-market trading, Ligand is 0.65% higher at $105.30 on the Nasdaq. Wednesday, Channel had closed 3.46% lesser at $1.2550 on the New York Stock Exchange.

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...

Predicting protein-ligand binding affinities is a critical problem in drug discovery and design. A majority of existing methods fail to accurately characterize and exploit the geometrically invariant ...

These modules allow the ProteinReDiff framework to capture intricate protein–ligand interactions, improve the fidelity of binding affinity predictions and enable more precise redesigns of ...

ProteinReDiff: Complex-based ligand-binding proteins redesign by equivariant diffusion-based generative models. Structural Dynamics, 2024; 11 (6) DOI: 10.1063/4.0000271 ...

Characterizing protein-ligand interactions is crucial for identifying the functions of uncharacterized proteins, studying regulatory mechanisms in cellular metabolism, and understanding the mechanisms ...

The analysis of protein-ligand binding sites plays a crucial role in the initial stages of drug discovery. Accurately predicting the ligand types that are likely to bind to protein-ligand binding ...

Visible-Light-Antenna Ligand-Enabled Samarium-Catalyzed Reductive Transformations. Journal of the American Chemical Society, 2024; 146 (30): 20904 DOI: 10.1021/jacs.4c05414 ...

The investigational dual androgen receptor antagonist and degrader BMS-986365 shows efficacy in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), according ...